am -
pm ET

Contact the Team

Alnylam Assist™ is comprised of dedicated, passionate individuals with diverse backgrounds and expertise in healthcare patient support and delivery. You are encouraged to contact them directly.

Alnylam Assist® Case Managers

Case Managers

Alnylam Assist™ is committed to the patient experience of those who start treatment with GIVLAARI® (givosiran). Each patient is partnered with a dedicated Case Manager who can provide support and assistance throughout treatment:

Insurance benefit verification and connecting with a Field Reimbursement Director

Financial assistance and affordable access options for eligible patients*

Facilitation of product orders

Connecting patients with a Patient Education Liaison (PEL)

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Alnylam Assist® Case Manager Kevin

Your Patient’s Dedicated Case Manager, Kevin

Alnylam Assist® Patient Education Liasons

Patient Education Liaisons

Patient Education Liaisons (PELs) are professionals with backgrounds in nursing who are experienced in educating patients and their families about matters related to acute hepatic porphyria (AHP). PELs support patients and their families in a number of ways:

Engaging patients and families with educational resources

Answering questions about AHP and treatment

Providing customized education, including one-on-one education or family meetings

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice

All diagnosis and treatment decisions should be made by the treating physician and their patients

Alnylam Assist® Field Reimbursement Directors

Field Reimbursement Directors

Field Reimbursement Directors (FRDs) are experienced professionals who provide education on the reimbursement process. FRDs can provide reimbursement education on:

GIVLAARI billing and coding requirements

Chart documentation best practices

Payer requirements

Payer issue identification and resolution

Personalized Support Throughout the Treatment Process

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Reaches Out. Step 3: Patient Support Provided

Alnylam Assist® Enrollment Process - Step 1: Complete Start Form. Step 2: Case Manager Contacts You and Your<br />
Patient. Step 3: Assistance for Patient and their Physician.

What is the enrollment process for the Alnylam Assist™ program?

Everything you need to know about the enrollment process and its requirements, including what your patients need to know, can be found on this site. View the enrollment process ›

Alnylam Assist® - FAQ

Find answers to other

Frequently Asked Questions ›

Enroll Your Patients Now

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›


Alnylam Assist® Start Form - To Print And Fax

& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle



GIVLAARI® (givosiran) is contraindicated in patients with known severe hypersensitivity to givosiran. Reactions have included anaphylaxis.

Anaphylactic Reaction

Anaphylaxis has occurred with GIVLAARI treatment (<1% of patients in clinical trials). Ensure that medical support is available to appropriately manage anaphylactic reactions when administering GIVLAARI. Monitor for signs and symptoms of anaphylaxis. If anaphylaxis occurs, immediately discontinue administration of GIVLAARI and institute appropriate medical treatment.

Hepatic Toxicity

Transaminase elevations (ALT) of at least 3 times the upper limit of normal (ULN) were observed in 15% of patients receiving GIVLAARI in the placebo-controlled trial. Transaminase elevations primarily occurred between 3 to 5 months following initiation of treatment.

Measure liver function tests prior to initiating treatment with GIVLAARI, repeat every month during the first 6 months of treatment, and as clinically indicated thereafter. Interrupt or discontinue treatment with GIVLAARI for severe or clinically significant transaminase elevations. In patients who have dose interruption and subsequent improvement, reduce the dose to 1.25 mg/kg once monthly. The dose may be increased to the recommended dose of 2.5 mg/kg once monthly if there is no recurrence of severe or clinically significant transaminase elevations at the 1.25 mg/kg dose.

Renal Toxicity

Increases in serum creatinine levels and decreases in estimated glomerular filtration rate (eGFR) have been reported during treatment with GIVLAARI. In the placebo-controlled study, 15% of patients receiving GIVLAARI experienced a renally-related adverse reaction. The median increase in creatinine at Month 3 was 0.07 mg/dL. Monitor renal function during treatment with GIVLAARI as clinically indicated.

Injection Site Reactions

Injection site reactions were reported in 25% of patients receiving GIVLAARI in the placebo-controlled trial. Symptoms included erythema, pain, pruritus, rash, discoloration, or swelling around the injection site. One (2%) patient experienced a single, transient, recall reaction of erythema at a prior injection site with a subsequent dose administration.

Blood Homocysteine Increased

Increases in blood homocysteine levels have occurred in patients receiving GIVLAARI. In the ENVISION study, during the open label extension, adverse reactions of blood homocysteine increased were reported in 15 of 93 (16%) patients treated with GIVLAARI. Measure blood homocysteine levels prior to initiating treatment and monitor for changes during treatment with GIVLAARI. In patients with elevated blood homocysteine levels, assess folate, vitamins B12 and B6. Consider treatment with a supplement containing vitamin B6 (as monotherapy or a multivitamin preparation).

Drug Interactions

Concomitant use of GIVLAARI increases the concentration of CYP1A2 or CYP2D6 substrates, which may increase adverse reactions of these substrates. Avoid concomitant use of GIVLAARI with CYP1A2 or CYP2D6 substrates for which minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP1A2 or CYP2D6 substrate dosage in accordance with approved product labeling.

Adverse Reactions

The most common adverse reactions that occurred in patients receiving GIVLAARI were nausea (27%) and injection site reactions (25%).


GIVLAARI® is indicated for the treatment of adults with acute hepatic porphyria (AHP).

For additional information about GIVLAARI, please see the full Prescribing Information.